Here's the earnings forecast out to 2029 for CSL shares

This biotech giant could see significant profit growth in the coming years.

| More on:
Young investor watching share chart in anticipation

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best things to see from a good company is rising net profit. That's usually what sends share prices higher over time and also helps fund larger dividend payments. Could CSL Ltd (ASX: CSL) shares see significant profit growth in the medium term?

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL20 Jan 202020 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.com.au

As we can see in the chart above, CSL shares have traded largely sideways over the past five years. In my mind, the rising earnings of the last few years have been catching up with the company's elevated price/earnings (P/E) ratio during that period, so the share price hasn't been able to push higher.

Excitingly, the company is expected to grow profit in each of the coming financial years. Let's look at what's expected of the ASX healthcare share with the help of UBS' profit estimates.

Predictions for FY25

The 2025 financial year is the current financial year, and we're already halfway through it!

UBS believes the CSL shares story is "heavily focused on gross profit margin improvement" at Behring. According to CSL, that division develops and delivers "high-quality medicines that treat people with rare and serious diseases." This includes a range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and other diseases.

The guided time window for the gross profit margin is between FY26 to FY28 to get back to pre-COVID levels of approximately 57%. The biggest improvement is expected in FY26, with a forecast rise of 200 basis points (2.00%), according to the broker.

UBS also noted that flat flu vaccine sales were expected in FY25, with other major manufacturers pointing to slow sales. US uptake has not returned to pre-COVID levels, and the weather is "warmer than usual in many parts of North America". UBS noted data that suggested the US retail channel saw 4% overall "market shrinkage" with CSL "looking worse".

The broker noted that CSL has already flagged lower orders from major retailers, so UBS believes the headwinds should not surprise investors.

However, UBS remains "optimistic about future recovery" although it's keeping in mind the "possibility of a less vaccine-friendly US administration."

Looking at the broker's forecast for FY25, UBS suggests CSL could generate US$16 billion of revenue and make a net profit of US$3.3 billion.

Expectations for FY26

Bearing in mind the comments above about expected profit margin improvement in the 2026 financial year, this year's net profit could significantly improve, which will help support CSL shares.

UBS forecasts CSL could generate US$17.1 billion of revenue in the 2026 financial year and make US$3.8 billion of net profit (up 16% year over year).

How about FY27?

According to UBS, the 2027 financial year could be another solid period with growth expected for the ASX healthcare share.

Revenue could rise to US$18.6 billion in FY27, helping net profit jump 18.5% to US$4.55 billion.

And FY28?

UBS is predicting ongoing double-digit profit growth for the biotech company to the end of the decade.

If the broker's projections come true, then in FY28, the business could make US$20 billion of revenue and US$5.2 billion of net profit, representing a 14.2% year-over-year increase.

And finally, FY29

The last year of this series of projections is the 2029 financial year. It could cap off an excellent period of growth for the company if UBS is right. In FY29, CSL is projected to generate US$21.6 billion of revenue and make US$5.8 billion of net profit.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »